HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NU-ICRF 505

an anthracenyl-amino acid conjugate; a topomerase I cleavage inducer; structure given in first source

Also Known As:

ICRF 505; NU 505; NU-ICRF-505

Networked: 6 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cummings, Jeffrey: 3 articles (05/2006 - 02/2002)
2.	Burchell, Brian: 2 articles (05/2006 - 02/2002)
3.	Ethell, Brian T: 2 articles (05/2006 - 02/2002)
4.	Boyd, Gary: 2 articles (01/2004 - 02/2002)
5.	Jodrell, Duncan I: 2 articles (01/2004 - 02/2002)
6.	Smyth, John F: 2 articles (01/2004 - 02/2002)
7.	Jardine, Lesley: 1 article (05/2006)
8.	Allen, John D: 1 article (01/2004)
9.	Friedberg, Thomas H: 1 article (01/2004)
10.	Maliepaard, Mark: 1 article (01/2004)

Related Diseases

1.	Colonic Neoplasms (Colon Cancer) 07/01/1996 - "NU/ICRF 505 was rapidly metabolized in nude mice to a product which represented the sole detectable form of the drug present in plasma and a chemosensitive human xenograft (HT-29 colon cancer). " 10/11/1996 - "In addition, NU/ICRF 505 significantly inhibited the growth of two human xenografts (HT-29 colon cancer and NX002 nonsmall-cell lung cancer) in nude mice after i.p. " 01/01/2004 - "In drug accumulation studies in human colon cancer cell lines NU/ICRF 505 was taken up avidly and retained in cells lacking UGTs (HCT116), whereas, following equally rapid uptake, it was cleared rapidly from cells displaying UGT activity (HT29) as glucuronide metabolites. " 05/01/2006 - "LC-MS was applied to measure rates of glucuronidation of two anticancer compounds (SN-38 and NU/ICRF 505) by patient colon cancer biopsies and paired normal colon. " 05/01/2006 - "Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon."
2.	Neoplasms (Cancer) 08/01/1996 - "Subsequent studies with the human lung (NX002), ovarian (A2780) and colon (HT29) cancer cell lines yielded evidence of formation of higher molecular weight DNA fragments in NX002 and A2780 cells in response to NU/ICRF 505 (5 microM). " 08/01/1996 - "Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505."
3.	Colorectal Neoplasms (Colorectal Cancer) 02/15/2002 - "As part of a program to identify novel mechanisms of resistance to topoisomerase I (topo I) inhibitors, the cellular pharmacology of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of clinically used irinotecan (CPT-11) and NU/ICRF 505, an anthraquinone-tyrosine conjugate, has been investigated in two human colorectal cancer (CRC) cell lines. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/11/1996 - "In addition, NU/ICRF 505 significantly inhibited the growth of two human xenografts (HT-29 colon cancer and NX002 nonsmall-cell lung cancer) in nude mice after i.p. "
5.	Breast Neoplasms (Breast Cancer) 01/01/2004 - "The ability of transport proteins to recognise NU/ICRF 505 as a substrate was evaluated in model systems either transfected with breast cancer-resistance protein 1 (Bcrp1), multidrug-resistance protein 2 (Mrp2) or Mrp3, or overexpressing MRP1 or P-170 glycoprotein. "

Related Drugs and Biologics

1.	Glucuronides
2.	DNA (Deoxyribonucleic Acid)
3.	Irinotecan (Camptosar)
4.	Topoisomerase I Inhibitors
5.	Uridine Diphosphate (UDP)
6.	Tyrosine (L-Tyrosine)
7.	Proteins (Proteins, Gene)
8.	Glycoproteins (Glycoprotein)
9.	Type I DNA Topoisomerases (Topoisomerase I)
10.	Carrier Proteins (Binding Protein)